Blueprint Medicines/BPMC

$95.12

1.71%
-
1D1W1MYTD1YMAX

About Blueprint Medicines

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Ticker

BPMC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Albers

Employees

655

Headquarters

Cambridge, United States

BPMC Metrics

BasicAdvanced
$5.73B
Market cap
-
P/E ratio
-$8.37
EPS
0.63
Beta
-
Dividend rate

What the Analysts think about BPMC

Analyst Ratings

Majority rating from 18 analysts.
Buy

Price Targets

Average projection from 17 analysts.
2.17% upside
High $125.00
Low $50.00
$95.12
Current price
$97.18
Average price target

BPMC Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-154.24% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$71.9M
27.26%
Net income
$-110.9M
-17.05%
Profit margin
-154.24%
-34.82%

BPMC Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.78%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.15
-$2.19
-$2.20
-$1.82
-
Expected
-$2.67
-$2.54
-$2.37
-$2.04
-$1.67
Surprise
-19.47%
-13.77%
-7.06%
-10.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Blueprint Medicines stock

Buy or sell Blueprint Medicines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing